Inactive Instrument

GENFIT Euronext Paris

Equities

FR0004163111

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 03:01:56 2024-07-03 EDT
3.735 ^EUR	0.00%

07-01	European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	MT
06-28	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	MT

GENFIT : Half-year report on GENFIT's liquidity contract with CM-CIC Securities

January 06, 2014 at 01:37 pm

MarketScreener.com By

Press Release

Communiqué de Presse

HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES

www . genfit . com

Lille (France), Boston (Massachusetts, United States), January 6, 2013 - GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces half-year report on GENFIT's liquidity contract with CM-CIC Securities.

Under the liquidity contract entrusted by GENFIT to CM-CIC Securities, the following assets appeared on the liquidity account as at December 31, 2013:

Latest news about GENFIT

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	07-01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	06-28	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-27	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	06-21	MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading	06-20	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	06-18	MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	06-14	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	06-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	06-11	MT
HC Wainwright Raises Genfit SA Price Target to $13 From $11, Maintains Buy Rating	06-11	MT
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	06-11	CI
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	06-10	MT
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	06-10	RE
US FDA approves Genfit and Ipsen's liver disease drug	06-10	RE
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	06-10	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	06-07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	06-05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	06-03	MT
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	05-31	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	05-30	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	05-29	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	05-14	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	05-13	MT

Chart GENFIT

Duration

Period

More charts

Company Profile

GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Q2 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+17.72%	44.87B
IQVIA HOLDINGS INC.	-10.33%	37.8B
LONZA GROUP AG	+37.55%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	31.32B
CELLTRION, INC.	-8.44%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.32B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.07B
MEDPACE HOLDINGS, INC.	+31.93%	12.5B
BIO-TECHNE CORPORATION	-7.67%	11.23B

Other Biotechnology & Medical Research